CIK: 0001131399
Total reported value
$599.2M
Reporting period: 2026-03-31 · Number of holdings: 13
GSK plc disclosed 13 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $599.2M and a quarterly turnover rate of 36.9%.
Browse other institutions with $100M to $1B AUMBrowse other institutions starting with "G"
GSK plc's disclosed holdings carry a Herfindahl concentration index of 0.160 — mathematically equivalent to about 6 equally-sized positions, well below its 13 actual disclosed holdings. That gap points to a strategy built around a small core of high-conviction bets rather than broad diversification.
Position sizes are fairly uniform across the portfolio (a coefficient of variation of 1.08), suggesting a disciplined, rules-based approach to how much capital goes into each idea.
No strong tilt toward either adding to existing winners or initiating outsized new positions was observed in the latest reported quarter.
Sector classification currently covers about 29% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Trim WVE
0.0% -$177.9M
Add VIR
0.0% $25.1M
Add CRSP
0.0% -$15.7M
Add BNTX
0.0% -$5.6M
Add IDYA
0.0% -$1.7M
Add CYTK
0.0% $806.8K
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | CRSP | CRISPR Therapeutics AG | Stock-Healthcare | 25.57% | +4.43% | — | |
| 2 | WVE | Wave Life Sciences Ltd. | Stock-Other | 22.08% | -16.74% | — | |
| 3 | BNTX | Biontech Se-adr | Stock-Other | 13.20% | +2.60% | — | |
| 4 | VIR | Vir Biotechnology INC | Stock-Other | 12.79% | +6.34% | — | |
| 5 | IDYA | Ideaya Biosciences INC | Stock-Other | 7.41% | +1.64% | — | |
| 6 | LYEL | Lyell Immunopharma INC | Stock-Other | 5.06% | -0.77% | — | |
| 7 | CYTK | Cytokinetics INC | Stock-Healthcare | 3.74% | +1.03% | — | |
| 8 | SPRO | Spero Therapeutics INC | Stock-Other | 3.59% | +0.91% | — | |
| 9 | FULC | Fulcrum Therapeutics INC | Stock-Other | 2.29% | -0.24% | — | |
| 10 | CVRX | Cvrx INC | Stock-Other | 1.59% | +0.69% | — | |
| 11 | BCYC | Bicycle Therapeutics Plc-adr | Stock-Other | 1.18% | -0.18% | — | |
| 12 | NKTX | Nkarta INC | Stock-Other | 1.11% | +0.38% | — | |
| 13 | RGNX | Regenxbio INC | Stock-Other | 0.38% | -0.11% | — |
Performance for Q3 2026
-10.8%
Performance Last 4 Quarters
-28.7%
Based on 5 months of available history
GSK plc's most significant position changes for 2026-03-31: Sold out: Senseonics Holdings INC (SENS); Sold out: Harvard Bioscience INC (HBIOUSD).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | VIR | Vir Biotechnology INC | +6.3% | — | Unchanged |
| 2 | CRSP | CRISPR Therapeutics AG | +4.4% | — | Unchanged |
| 3 | BNTX | Biontech Se-adr | +2.6% | — | Unchanged |
| 4 | IDYA | Ideaya Biosciences INC | +1.6% | — | Unchanged |
| 5 | CYTK | Cytokinetics INC | +1% | — | Unchanged |
| 6 | SPRO | Spero Therapeutics INC | +0.9% | — | Unchanged |
| 7 | CVRX | Cvrx INC | +0.7% | — | Unchanged |
| 8 | NKTX | Nkarta INC | +0.4% | — | Unchanged |
| 9 | RGNX | Regenxbio INC | -0.1% | — | Unchanged |
| 10 | BCYC | Bicycle Therapeutics Plc-adr | -0.2% | — | Unchanged |
| 11 | FULC | Fulcrum Therapeutics INC | -0.2% | — | Unchanged |
| 12 | LYEL | Lyell Immunopharma INC | -0.8% | — | Unchanged |
| 13 | WVE | Wave Life Sciences Ltd. | -16.7% | — | Unchanged |
| 14 | SENS | Senseonics Holdings INC | — | EXIT | Sold out |
| 15 | HBIOUSD | Harvard Bioscience INC | — | EXIT | Sold out |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026-03-31 | 2026-05-14 | 13F-HR | View on EDGAR |
| 2025-12-31 | 2026-02-12 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0001626632
Total reported value
$599.1M
156 stks
2021-12-31
Stale — no recent filing
AUM within 0.0% of this institution
CIK 0001973849
Total reported value
$598.8M
113 stks
2026-06-30
AUM within 0.1% of this institution
CIK 0001567992
Total reported value
$599.6M
153 stks
2024-03-31
Stale — no recent filing
AUM within 0.1% of this institution
Institutions with overlapping top holdings
CIK 0001663801
Total reported value
$43.5M
5 stks
2024-09-30
Stale — no recent filing
2 of the top 5 holdings overlap, including Biontech Se-adr
CIK 0001274403
Total reported value
$677.1M
10 stks
2026-03-31
1 of the top 5 holdings overlap, including Vir Biotechnology INC
CIK 0001316915
Total reported value
$20.0M
65 stks
2023-03-31
Stale — no recent filing
1 of the top 5 holdings overlap, including Vir Biotechnology INC